ECTRIMS 2023 | Cerebral blood flow and its impact on neuroinflammation in MS

Dejan Jakimovski, MD, PhD, Buffalo Neuroimaging Analysis Center, Buffalo, NY, highlights a study examining the relationship between 21 proteomic biomarkers and the total cerebral arterial blood flow in multiple sclerosis (MS) patients. The central debate focuses on whether low blood flow to the brain leads to increased neurodegeneration or exacerbates the inflammatory state of MS. Results indicated that individuals with reduced cerebral blood flow exhibited both heightened neurofilament light chain levels (indicative of neural damage) and elevated neuroinflammatory biomarkers, particularly CXCL13. Interestingly, hypoperfusion was most closely associated with proteomic scores related to neuroinflammation and immunomodulation rather than neurodegeneration. The findings suggest that addressing hypoperfusion could be pivotal in managing neuroinflammation in MS. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.